# EDGAR Filing Document

**Accession Number:** 0000911216
**File Stem:** 0001654954-23-001757
**Filing Date:** 2023-2
**Character Count:** 26168
**Document Hash:** e3fd61dc779e180013c820073044f84a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-23-001757.hdr.sgml**: 20230215

**ACCESSION NUMBER**: 0001654954-23-001757

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230215

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230215

**DATE AS OF CHANGE**: 20230215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PALATIN TECHNOLOGIES INC
- **CENTRAL INDEX KEY:** 0000911216
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 954078884
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15543
- **FILM NUMBER:** 23633727

**BUSINESS ADDRESS:**
- **STREET 1:** 4B CEDAR BROOK DRIVE
- **CITY:** CRANBURY
- **STATE:** NJ
- **ZIP:** 08512
- **BUSINESS PHONE:** 609-495-2200

**MAIL ADDRESS:**
- **STREET 1:** 4B CEDAR BROOK DRIVE
- **CITY:** CRANBURY
- **STATE:** NJ
- **ZIP:** 08512

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INTERFILM INC
- **DATE OF NAME CHANGE:** 19930825

?xml version="1.0" encoding="utf-8"?ptn_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

____________________

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported): **February 15, 2023**

---

| |
|:---|
| **Palatin Technologies, Inc.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-15543** | **95-4078884** |
| (State or other jurisdiction | (Commission | (IRS employer |
| of incorporation) | File Number) | identification number) |

---

---

| | |
|:---|:---|
| **4B Cedar Brook Drive, Cranbury, NJ** | **08512** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(609) 495-2200**

**<u>Not Applicable</u>**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of Each Class | Trading Symbol | Name of Each Exchange<br>on Which Registered |
| **Common Stock, par value $.01 per share** | **PTN** | **NYSE American** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02 Results of Operations and Financial Condition.**

On February 15, 2023, we issued a press release including results for our quarter ended December 31, 2022 and announcing a teleconference and webcast to be held February 15, 2023, at 11:00 a.m. Eastern time, which will include a discussion on results of operations in greater detail and an update on corporate developments. We have attached a copy of the press release as an exhibit to this report.

The information in this Item 2.02 and the corresponding information in the attached Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information contained in this Item 2.02 and the corresponding information in the attached Exhibit 99.1 shall not be incorporated into any registration statement or other document filed with the Securities and Exchange Commission by the company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits:

---

| | |
|:---|:---|
| [99.1](ptn_ex991.htm) | [Press Release dated February 15, 2023](ptn_ex991.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | PALATIN TECHNOLOGIES, INC. | PALATIN TECHNOLOGIES, INC. |
| Date: February 15, 2023 | By: | /s/ Stephen T. Wills |
|  |  | Stephen T. Wills, CPA, MST<br>Executive Vice President, Chief Financial Officer<br>and Chief Operating Officer |

---

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| [99.1](ptn_ex991.htm) | [Press Release dated February 15, 2023](ptn_ex991.htm) |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update**

· *Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing* 

*o* *Patient Enrollment on Track* 

*o* *Topline Results Currently Expected Mid-Calendar Year 2023* 

· *Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Commenced* 

*o* *First Patient Dosed* 

*o* *Planned Interim Analysis Targeted for First Half Calendar Year 2023* 

*o* *Topline Results Currently Expected Second Half Calendar Year 2023* 

· *Phase 2 Clinical Study of Bremelanotide in Patients with Diabetic Kidney Disease* 

*o* *Complete Enrollment Targeted for Third Quarter Calendar Year 2023* 

*o* *Topline Results Currently Expected First Quarter Calendar Year 2024* 

· *Vyleesi® - Net Product Revenue Increased 18% and Prescriptions Dispensed Increased 12% Over the Prior Quarter* 

· *Closed on a $10.0 Million Registered Direct Offering* 

· *Received $4.7 Million of Non-Dilutive Funding Through NJ Economic Development Program* 

· *Teleconference and Webcast to be held on February 15, 2023, at 11:00 AM ET* 

CRANBURY, NJ – February 15, 2023 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal second quarter ended December 31, 2022.

"We continue to execute on our strategy that the melanocortin system is an important mechanism for the resolution of inflammation and promotion of tissue repair," said Carl Spana, Ph.D., President and CEO of Palatin. "We currently have three active melanocortin-based clinical programs: our MELODY-1 Phase 3 dry eye disease trial, a Phase 2 ulcerative colitis trial, and a Phase 2 diabetic kidney disease trial, all with data readouts throughout the next five calendar quarters."

Dr. Spana further commented, "We are pleased with Vyleesi's continued quarter over quarter increases across all value metrics, notably net product sales increased 18% and prescriptions dispensed increased 12% over the prior quarter. We are excited that net product revenue of approximately $1 million for the quarter ended December 31, 2022, exceeded Vyleesi operating expenses."

**<u>Business Highlights and Recent Updates</u>**

· *Anti-Inflammatory / Autoimmune Programs* 

o PL9643 melanocortin agonist for the treatment of dry eye disease (DED)

– Patient enrollment on track. <br> – Topline data readout currently expected mid-calendar year 2023. <br> – Additional trial information, including inclusion and exclusion criteria, can be found at https://clinicaltrials.gov/ via the identifier NCT04268069.

*-More-*

o PL8177 oral melanocortin agonist for the treatment of ulcerative colitis (UC):

---

| |
|:---|
| First patient dosed in a Phase 2 oral formulation study of PL8177 in patients with UC in the fourth quarter calendar year 2022. |
| Interim assessment is currently expected to occur in the first half of calendar year 2023. |
| Topline data readout is currently expected in the second half of calendar year 2023. |
| Additional trial information, including inclusion and exclusion criteria, can be found at https://clinicaltrials.gov/ via the identifier NCT05466890. |

---

o Bremelanotide BREAKOUT study (BMT 701) in patients with diabetic kidney disease:

---

| |
|:---|
| Enrollment initiated in the Phase 2 study in the first quarter of calendar year 2023. |
| Complete enrollment targeted for third quarter calendar year 2023. |
| Topline results currently expected first quarter calendar year 2024. |
| Additional trial information, including inclusion and exclusion criteria, can be found at https://clinicaltrials.gov/ via the identifier NCT05709444. |

---

· *Vyleesi® (bremelanotide injection) / Hypoactive Sexual Desire Disorder (HSDD):* Goal of the Vyleesi program is to demonstrate commercial product value in the marketplace with an objective of re-licensing the U.S. rights to a committed women's healthcare company.

o For the fiscal second quarter ended December 31, 2022:

---

| |
|:---|
| Gross product sales were $2.6 million, an increase of 14% over the prior quarter, and an increase of 238% over the comparable quarter last year. |
| Net product revenue of $1 million increased 18% over the prior quarter and increased 1,323% over the comparable quarter last year. |
| Total prescriptions dispensed increased 12% over the prior quarter and increased 134% over the comparable quarter last year. |
| Refill rates, commercial insurance reimbursement, and net revenue per prescription dispensed increased over the prior quarter and comparable quarter last year. |

---

o Patients and healthcare providers can learn more about HSDD and Vyleesi at <u>www.vyleesi.com</u> and <u>www.vyleesipro.com</u>.

· *Other:* 

o The Company participated in the State of New Jersey's Technology Business Tax Certificate Transfer Program sponsored by The New Jersey Economic Development Authority. The Program enables approved biotechnology companies with unused Net Operating Losses ("NOLs") and unused research and development credits ("R&D credits") to sell these tax benefits to unaffiliated, profitable corporate taxpayers in the State of New Jersey. The Company received final approval in December 2022 for the sale of NOLs and R&D credits that resulted in the receipt of $4,674,999 in January 2023. As a result, the Company recorded an income tax benefit for the three and six months ended December 31, 2022, and a corresponding receivable as of December 31, 2022.

*-More-*

o Registered Direct Offering: On October 31, 2022, Palatin entered into a securities purchase agreement with an institutional investor, selling and issuing an aggregate of (i) 1,020,000 shares of Palatin common stock, $0.01 par value per share, (ii) prefunded warrants (the "Pre-Funded Warrants") to purchase up to 798,182 shares of Palatin common stock, and (iii) common warrants (the "Common Warrants") to purchase up to 1,818,182 shares of Palatin common stock. Each share of common stock was offered with one accompanying Common Warrant for a combined offering price of $5.50. Each Pre-Funded Warrant was offered with one accompanying Common Warrant for a combined offering price of $5.4999. The Offering was completed on November 2, 2022 with the Company receiving gross proceeds of $10 million. The Common Warrants have an exercise price of $5.83 per share, are exercisable beginning six months after the date of issuance and will expire five and one-half years from the date of issuance. The Pre-Funded Warrants had an exercise price of $0.0001 per share and subsequent to December 31, 2022, the institutional investor exercised all outstanding Pre-Funded Warrants to purchase 798,182 shares of Palatin's common stock.

**<u>Fiscal Second Quarter Ended December 31, 2022 Financial Results</u>**

***Revenue***

Total revenue consists of gross product sales of Vyleesi, net of allowances and accruals, and license and contract revenue.

Vyleesi gross product sales to pharmacy distributors were $2.6 million, with net product revenue of $1,026,416, compared to gross product sales of $0.8 million and net product revenue of $72,140 for the comparable quarter last year. Gross product sales increased 238% and net product revenue increased 1,323% over the comparable quarter last year.

For the quarter ended December 31, 2021, Palatin recognized $250,000 in license and contract revenue pursuant to its license agreement with Fosun Pharma.

***Operating Expenses***

Total operating expenses were $6.6 million, compared to $8.8 million for the comparable quarter last year. The decrease in operating expenses was mainly the result of lower spending on our development programs and the gain recognized as a result of amending certain minimum purchase commitments.

***Other Income / (Expenses)***

Total other expense, net, consists mainly of unrealized foreign currency transaction losses of $693,231 and $234,078, respectively, for the quarters ended December 31, 2022, and 2021.

<u> </u>

*-More-*

***Cash Flows***

Palatin's net cash used in operations was $8.8 million, compared to net cash used in operations of $6.3 million for the same period last year. The increase in net cash used in operations is mainly due to working capital changes for the quarter ended December 31, 2022.

***Net Loss***

Palatin's net loss was $1.4 million, or $(0.13) per basic and diluted common share, compared to a net loss of $8.7 million, or $(0.91) per basic and diluted common share for the comparable period last year.

The decrease in net loss over the comparable quarter last year, was mainly due to the recognition of an income tax benefit of $4.7 million, a decrease in operating expenses of $2.2 million and an increase in net product revenue of Vyleesi.

***Cash Position***

As of December 31, 2022, Palatin's cash and cash equivalents were approximately $21.2 million plus $6.5 million of accounts and other receivables, compared to cash and cash equivalents of $21.2 with $2.0 million of accounts receivable as of September 30, 2022, and $29.9 million with $1.8 million of accounts receivable as of June 30, 2022.

Based on its current operating plan, Palatin believes that existing cash and cash equivalents and receivables will be sufficient to fund currently anticipated operating expenses through calendar year 2023.

**<u>Conference Call / Webcast</u>**

Palatin will host a conference call and audio webcast on February 15, 2023, at 11:00 a.m. Eastern Time to discuss the results of operations in greater detail and provide an update on corporate developments. Individuals interested in listening to the conference call live can dial 1-888-506-0062 (US) or 1-973-528-0011 (International), conference ID 928705. The audio webcast and replay can be accessed by logging on to the "Investor/Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and audio webcast replay will be available one hour after the completion of the call. To access the telephone replay, dial 1-877-481-4010 (US) or 1-919-882-2331 (International), passcode 47637. The webcast and telephone replay will be available through March 1, 2023.

**<u>About Melanocortin Receptor Agonists and Inflammation</u>**

The melanocortin receptor ("MCr") system has effects on inflammation, immune system responses, metabolism, food intake, and sexual function. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have medically significant pharmacological effects.

Many tissues and immune cells located in the eye (and other places, for example the gut and kidney) express melanocortin receptors, empowering our opportunity to directly activate natural pathways to resolve disease inflammation.

*-More-*

**<u>About Palatin</u>**

Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at <u>www.Palatin.com</u> and follow Palatin on Twitter at @PalatinTech.

**<u>Forward-looking Statements</u>**

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about market potential of Vyleesi and other Palatin products in development, clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates, market potential for product candidates, and potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, Palatin's ability to establish and maintain the capability for manufacturing, marketing and distribution of Vyleesi, sales of Vyleesi in the United States and elsewhere in the world, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

---

| | |
|:---|:---|
| **Investor Inquiries:** | **Media Inquiries:** |
| Stephen T. Wills, CPA, MST  | Paul Arndt, MBA, LifeSci Advisors |
| CFO/COO (609) 495-2200  | Managing Director (646) 597-6992 |
| Info@Palatin.com  | Paul@LifeSciAdvisors.com |

---

Palatin Technologies® and Vyleesi® are registered trademarks of Palatin Technologies, Inc.

###

*(Financial Statement Data Follows)* 

---

| | | | | |
|:---|:---|:---|:---|:---|
| **PALATIN TECHNOLOGIES, INC.** | **PALATIN TECHNOLOGIES, INC.** | **PALATIN TECHNOLOGIES, INC.** | **PALATIN TECHNOLOGIES, INC.** | **PALATIN TECHNOLOGIES, INC.** |
| **and Subsidiary** | **and Subsidiary** | **and Subsidiary** | **and Subsidiary** | **and Subsidiary** |
| **Consolidated Statements of Operations** | **Consolidated Statements of Operations** | **Consolidated Statements of Operations** | **Consolidated Statements of Operations** | **Consolidated Statements of Operations** |
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | (unaudited) |
|  | **Three Months Ended**<br> **December 31,** | **Three Months Ended**<br> **December 31,** | **Six Months Ended**<br> **December 31,** | **Six Months Ended**<br> **December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| REVENUES |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Product revenue, net | $1026416 | $72140 | $1896070 | $231622 |
| &nbsp;&nbsp;&nbsp; License and contract | - | 250000 | - | 250000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total revenues | 1026416 | 322140 | 1896070 | 481622 |
| OPERATING EXPENSES |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Cost of products sold | 98707 | 29171 | 185203 | 83104 |
| &nbsp;&nbsp;&nbsp; Research and development | 4367538 | 5426397 | 10394569 | 8911161 |
| &nbsp;&nbsp;&nbsp; Selling, general and administrative | 3174344 | 3317760 | 6683142 | 7154302 |
| &nbsp;&nbsp;&nbsp; Gain on purchase commitment | (1027322) | - | (1027322) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total operating expenses | 6613267 | 8773328 | 16235592 | 16148567 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss from operations | (5586851) | (8451188) | (14339522) | (15666945) |
| OTHER INCOME (EXPENSE) |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Investment income | 186473 | 1563 | 274962 | 2973 |
| &nbsp;&nbsp;&nbsp; Foreign currency loss | (693231) | (234078) | (274855) | (126719) |
| &nbsp;&nbsp;&nbsp; Interest expense | (5487) | (2773) | (15089) | (8404) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total other income (expense), net | (512245) | (235288) | (14982) | (132150) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss before income taxes | (6099096) | (8686476) | (14354504) | (15799095) |
| Income tax benefit | 4674999 | - | 4674999 | - |
| NET LOSS | $(1424097) | $(8686476) | $(9679505) | $(15799095) |
| Basic and diluted net loss per common share | $(0.13) | $(0.91) | $(0.95) | $(1.66) |
| Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share | 10802863 | 9531071 | 10215616 | 9530252 |

---

---

| | | |
|:---|:---|:---|
| **PALATIN TECHNOLOGIES, INC**. | **PALATIN TECHNOLOGIES, INC**. | **PALATIN TECHNOLOGIES, INC**. |
| **and Subsidiary** | **and Subsidiary** | **and Subsidiary** |
| **Consolidated Balance Sheets** | **Consolidated Balance Sheets** | **Consolidated Balance Sheets** |
| (unaudited) | (unaudited) | (unaudited) |
|  | **December 31,**<br> **2022** | **June 30,**<br> **2022** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp; Cash and cash equivalents | $21182839 | $29939154 |
| &nbsp;&nbsp;&nbsp; Accounts receivable | 1806990 | 1780020 |
| &nbsp;&nbsp;&nbsp; Other receivables | 4674999 |  |
| &nbsp;&nbsp;&nbsp; Inventories | 759268 | 944471 |
| &nbsp;&nbsp;&nbsp; Prepaid expenses and other current assets | 2127230 | 1932454 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current assets | 30551326 | 34596099 |
| Property and equipment, net | 674567 | 539314 |
| Right-of-use assets - operating leases | 693729 | 878465 |
| Other assets | 56916 | 56916 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total assets | $31976538 | $36070794 |
| **LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY**  |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp; Accounts payable  | $820304 | $3157617 |
| &nbsp;&nbsp;&nbsp; Accrued expenses | 6065821 | 6875216 |
| &nbsp;&nbsp;&nbsp; Short-term operating lease liabilities | 335732 | 371124 |
| &nbsp;&nbsp;&nbsp; Short-term finance lease liabilities | 103622 | 100921 |
| &nbsp;&nbsp;&nbsp; Other current liabilities | 4094600 | 5754986 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current liabilities | 11420079 | 16259864 |
| Long-term operating lease liabilities | 380161 | 529398 |
| Long-term finance lease liabilities | 99912 | 152407 |
| Other long-term liabilities | 3732800 | 2861250 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities | 15632952 | 19802919 |
| Series B and Series C Redeemable Convertible Preferred Stock of $0.01 par value: authorized 9,000,000 shares, 9,000,000 shares issued and outstanding as of June 30, 2022, with a liquidiation preference of $15,000,000  |  | 15000000 |
| Escrowed proceeds | - | (15000000) |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp; Preferred stock of $0.01 par value – authorized 10,000,000 shares (including amounts authorized for |  |  |
| &nbsp;&nbsp;&nbsp; Series B and Series C Redeemable Convertible Preferred Stock): shares issued and outstanding |  |  |
| &nbsp;&nbsp;&nbsp; designated as follows: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Series A Convertible: authorized 4,030 shares as of December 31, 2022: issued and outstanding 4,030 shares |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as of December 31, 2022 and June 30, 2022 | 40 | 40 |
| &nbsp;&nbsp;&nbsp; Common stock of $0.01 par value – authorized 300,000,000 shares: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; issued and outstanding 10,354,498 shares as of December 31, 2022 and 9,270,947 shares as of June 30, 2022  | 103545 | 92709 |
| &nbsp;&nbsp;&nbsp; Additional paid-in capital | 413913202 | 404168822 |
| &nbsp;&nbsp;&nbsp; Accumulated deficit  | (397673201) | (387993696) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total stockholders' equity  | 16343586 | 16267875 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities, redeemable convertible preferred stock, and stockholders' equity | $31976538 | $36070794 |

---